GlassScriptPhysician profile
Eunice Sanchez
NPI 1891301446
$2,657.39
in general payments reported to CMS, 2019-2025
17 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.85 · 2022: $291 · 2023: $728 · 2024: $575 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.33 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $769.98 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $452.03 | 2022-2025 | Entyvio |
| Janssen Biotech, INC. | $365.69 | 2021-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $215.71 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $174.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $122.65 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $80.30 | 2023-2025 | Dupixent |
| Novo Nordisk INC | $75.01 | 2022-2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $73.02 | 2023-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $63.22 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $61.43 | 2025 | |
| Abbvie INC. | $53.37 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.41 | 2023-2024 | Cyltezo |
| Braintree Laboratories, INC. | $42.34 | 2022-2025 | Sutab, Suflave |
| Qol Medical, LLC | $21.19 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.81 | 2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $17.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunice Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.